Citius Oncology prices $9 million offering; shares down over 5%
Source: SeekingAlpha
2025-09-09 08:42:16 ET
More on Citius Pharmaceuticals, Citius Oncology
- Citius Oncology: Is A Lymphir Launch Coming Too Late?
- Citius Oncology announces pricing of $9 million public offering
- Cencora distribution deal boosts Citius shares
- Seeking Alpha’s Quant Rating on Citius Pharmaceuticals
- Historical earnings data for Citius Pharmaceuticals
Read the full article on Seeking Alpha
For further details see:
Citius Oncology prices $9 million offering; shares down over 5%
Citius Oncology Inc.
NASDAQ: CTOR
CTOR Trading
-0.79% G/L:
$0.50 Last:
110,852 Volume:
$0.548 Open:
CTOR Latest News
March 31, 2026 09:11:00 am
Citius Oncology Provides Commercial Update on LYMPHIR(TM) Launch Highlighting Early Adoption and Expanding Clinical Development
March 24, 2026 08:00:00 am
Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR(TM) in Discussions with Leading Cutaneous Lymphoma Experts
